Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Vor Biopharma ( (VOR) ) has shared an update.
On February 3, 2025, Vor Biopharma’s board approved a stock option repricing to reduce the exercise price of certain options to $1.34 per share, impacting approximately 6.76 million shares. This move aims to motivate and retain employees while avoiding stock dilution or additional cash outlays, with a retention period set until February 3, 2026 or earlier under specific conditions.
More about Vor Biopharma
Vor Biopharma Inc. operates in the biopharmaceutical industry, focusing on the development of innovative therapies for the treatment of cancer and other serious diseases. The company is committed to advancing its pipeline of genetically engineered hematopoietic stem cell products.
YTD Price Performance: 30.36%
Average Trading Volume: 755,969
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $100.3M
For a thorough assessment of VOR stock, go to TipRanks’ Stock Analysis page.
